Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthcare.
The US Senate Committee on Health, Education and Labour have recently held a hearing looking into the prices of drugs in the US.
After the price negotiations between the US Government Medicare branch and US-based pharma companies resulted in the first 10 drugs chosen for price capping, and the parameters for this was decided, there has been considerable uproar from the pharmaceutical industry.
In the hearing, companies have been given the floor to challenge the Inflation Reduction Act protocols, inputted by the Biden Administration. Three of the biggest pharmaceutical companies in the world have come to testify at the hearing: Johnson & Johnson CEO Joaquin Duato, Merck CEO Robert Davis, and Bristol Myers Squibb CEO Chris Boerner all took the stand to face a grilling from the Senate.
Senator Bernie Sanders published a report earlier this week demonising the three pharma giants for marking up their prescription drugs to frankly prohibitive prices, making them inaccessible to a large proportion of Americans.
The main quarrel that Sanders had with the companies is that they charge a shockingly high price for drugs in the US compared to what they charge in other countries, hence calling these particular plaintiffs to the hearing.
Sanders quotes the price differences as follows:
• Bristol Myers Squibb charges an annual list price of US$7,100 for Eliquis in the US, compared to around US$900 in Canada and US$650 in France
• J&J’s Stelara, for the treatment of Crohn’s disease, is US$79,000 in North America, but US$16,000 in the UK
• Merck’s Januvia is approximately US$6,000 in the US compared to US$900 in Canada and US$200 in France.
Duato, Davis, and Boerner defended the list prices, stating that the US drugs carry more benefits to patients by being available on the market earlier compared to these other countries.
"This is in stark contrast to many systems outside the United States, which while they may deliver lower prices, carry an often overlooked trade off that patients often wait longer for new medicines," stated Boerner.
The executives also cited the impact the price negotiations would have on innovation in the field, by pointing out that if they didn’t gain revenue from their marketable prescription medications, they would not be able to reinvest in drug discovery and development for new medicines. As these companies are main drivers of progression in drug discovery, such as with J&J's Innovative Medicine branch, and large investments into the start-up and biotech space, the impact on furthering the development of this area of medicine could be huge.
Sources:
NBC News. Pharma CEOs grilled by senators over sky-high drug prices. [Date accessed 12/02/2024] www.nbcnews.com/health/health-news/pharma-ceos-grilled-senators-sky-high-drug-prices-rcna137993
Forbes. Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here’s What To Watch For. [Date accessed 12/02/2024] www.forbes.com/sites/tylerroush/2024/02/08/pharma-ceos-will-testify-today-over-prescription-drug-prices-heres-what-to-watch-for/?sh=efdb2d93d7b9
See more on the Inflation Reduction Act and what it means for the pharmaceutical industry by clicking the button below.
Related News
-
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance